| Protocol No. | UW25121 |
||
|---|---|---|---|
| Principal Investigator | Miller, Megan | ||
| Phase | N/A | ||
| Age Group | Adult | ||
| Management Group(s) | Palliative Care | ||
|
Title
Description
Objective
Treatment Participants will complete surveys at baseline , then at 3-, 6-, and 12 months post treatment initiation. The baseline data collection target is within 14 days of initiating cancer-directed treatment, with an allowable window of up to 60 days. For participants receiving cytotoxic chemotherapy, baseline completion will be prioritized prior to the first infusion or within 3 days after infusion whenever feasible, to minimize completion during the period when treatmentrelated symptoms are often most severe. Chemotherapy cycle number and day-in-cycle at the time of survey completion will be recorded and incorporated in analyses to account for within-cycle variability.
Key Eligibility
Inclusion criteria are:
Applicable Disease Sites
Participating Institutions
|
|||